Seizing growth opportunities in the UK life science sector

The UK life science sector is on track for significant expansion, driven by breakthroughs in therapeutics, diagnostics, digital health, and translational science.

For brokers, this represents a tangible opportunity to support ambitious SMEs navigating raising capital, clinical trials, regulatory approvals, and commercial scaling.

The growth story is backed by strong forecasts; the Government believes the UK life science sector could grow by £41 billion (165%) by 2035*, making the UK the leading life science economy in Europe and the third largest in the world, behind only the United States and China.

That’s an opportunity that can’t be ignored. But it’s also a sector where risk evolves quickly as businesses move from R&D into clinical stages, manufacturing, partnerships, and international markets.

We’ve created a tailored offer for the sector designed to go beyond standard insurer services, helping brokers support clients through complex regulatory environments and fast-changing exposures.

Macro trends shaping growth and why they matter to brokers

Life science growth in the UK is being fuelled by a combination of policy ambition, investment appetite, and innovation clusters. Hubs such as Cambridge and Oxford continue to attract talent and capital, while global M&A interest is creating both opportunities and pressures for high-potential SMEs.

For brokers, this matters because it changes the nature of client conversations. Life science businesses may be scaling headcount quickly, raising funds, entering partnerships, working with contract research organisations, and taking on new obligations around data, quality, and regulatory compliance. Each step forward can introduce new liabilities, and the earlier brokers understand the pattern, the easier it is to protect growth and avoid gaps at placement and renewal.

Where clients need risk advice most

Life science is characterised by pace, complexity, and constant change. Risk rarely sits neatly in a single policy line. Rather, it often emerges across cyber, operational resilience, supply chain dependency, regulatory exposure, and reputation. And the closer a business gets to commercialisation, the greater the potential impact of disruption.

Some of the most common pressure points include:

Protecting R&D spend and intellectual property (IP)

Many life science SMEs are built on a small number of assets: a compound, a device, a platform, or a dataset. That makes IP and R&D investment central to value, but also risk. A cyber incident, contractual dispute, third-party failure, or data integrity issue can quickly threaten momentum, valuation and stakeholder confidence.

Clinical trials and regulatory environments

Businesses navigating clinical stages face heightened scrutiny, documentation demands, and stakeholder expectations. Regulatory approvals, reporting standards, and governance requirements can all affect operational risk and introduce potential liability if things go wrong. Brokers can add value by understanding where the client sits in the R&D-to-commercialisation journey and how that changes their risk profile.

Cybersecurity and data

Cyberattacks present a particular risk for life science companies, with many relying on connected operational technology and highly sensitive IP. The barrier to launching cyberattacks has also lowered. Tools can be acquired on the dark web and used without extensive technical expertise. Bad actors are also employing AI-enabled techniques to automate and scale attacks, adding new challenges for security teams.

Supply chain fragility and third-party dependency

Life science businesses often rely on specialist materials and components that may come from a small number of niche suppliers. Temperature-sensitive goods can also increase the risk of spoilage in transit or storage. Overlay that with an uncertain geopolitical climate, and supply chain resilience becomes a real operational concern, not just a procurement issue.

Business interruption, product withdrawal, and recall exposures

Businesses operating in highly regulated sub-sectors, such as pharmaceuticals and medical devices, can face significant business interruption exposures alongside separate product withdrawal and recall risks. Understanding how products are manufactured, distributed, and relied upon helps brokers anticipate the operational, financial, and reputational impact of disruption, and structure cover that reflects these distinct exposures.

Framing the broker conversation: risk-enabled growth

For high-growth life science SMEs, insurance discussions are most effective when they address genuine business needs. The strongest broker conversations frame risk management as part of the growth journey, helping clients build resilience that supports investment, productive partnerships, and regulatory confidence.

That means asking better questions at quote and renewal, such as:

• Where are you in the R&D-to-commercialisation journey, and what could change in the next 12-18 months?
• Which third parties are critical to delivery (Contract Research Organisations, manufacturers, labs, cloud platforms) and what happens if they fail?
• How is sensitive data governed, accessed and protected, and how would you respond to an incident?
• What would a disruption mean in terms of trial timelines, customer commitments, funding milestones, and reputation?

The aim is to help clients anticipate how exposures evolve as they scale, and to place cover that keeps pace.

The opportunity for brokers

While the UK life science sector offers brokers a significant growth opportunity, it also demands a specialist mindset. As SMEs move from innovation to commercial scale, exposures shift quickly across data, regulation, operational resilience, and supply chain dependency.

Brokers who can help clients understand those risks early, and position risk management as a competitive advantage, will be best placed to build long-term relationships in one of the UK’s most ambitious and valuable growth sectors.

Supporting growth at every stage

High-growth life science SMEs need insurance that scales with them. A life science-focused proposition supports brokers in structuring programmes that reflect the realities of fundraising, clinical development, international expansion, and evolving regulatory demands. This includes support around intellectual property exposures, business continuity planning, and tailored insurance solutions designed to protect innovation as businesses scale.